Javier Cortés

67.7k total citations · 22 hit papers
726 papers, 28.6k citations indexed

About

Javier Cortés is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Javier Cortés has authored 726 papers receiving a total of 28.6k indexed citations (citations by other indexed papers that have themselves been cited), including 581 papers in Oncology, 318 papers in Pulmonary and Respiratory Medicine and 224 papers in Cancer Research. Recurrent topics in Javier Cortés's work include HER2/EGFR in Cancer Research (303 papers), Cancer Treatment and Pharmacology (276 papers) and Advanced Breast Cancer Therapies (243 papers). Javier Cortés is often cited by papers focused on HER2/EGFR in Cancer Research (303 papers), Cancer Treatment and Pharmacology (276 papers) and Advanced Breast Cancer Therapies (243 papers). Javier Cortés collaborates with scholars based in Spain, United States and United Kingdom. Javier Cortés's co-authors include José Baselga, Graham Ross, Nadia Harbeck, Sandra M. Swain, Emma Clark, José Baselga, Sung‐Bae Kim, Fátima Cardoso, Andreas Schneeweiß and Mark Benyunes and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Javier Cortés

697 papers receiving 28.0k citations

Hit Papers

Breast cancer 2007 2026 2013 2019 2019 2011 2015 2011 2013 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Breast cancer
    2019 2.0k citations Nadia Harbeck, Javier Cortés et al. profile →
  2. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
    2011 1.8k citations José Baselga, Javier Cortés et al. New England Journal of Medicine profile →
  3. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
    2015 1.4k citations Sandra M. Swain, José Baselga et al. New England Journal of Medicine profile →
  4. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
    2011 807 citations Javier Cortés, Joyce O’Shaughnessy et al. profile →
  5. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
    2013 774 citations Virginia McNally, Javier Cortés et al. profile →
  6. Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
    2010 700 citations David Miles, Arlene Chan et al. Journal of Clinical Oncology profile →
  7. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
    2013 700 citations Sandra M. Swain, Sung‐Bae Kim et al. profile →
  8. Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer
    2007 659 citations Maurizio Scaltriti, Federico Rojo et al. JNCI Journal of the National Cancer Institute profile →
  9. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
    2022 594 citations Javier Cortés, Hope S. Rugo et al. New England Journal of Medicine profile →
  10. Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer
    2016 511 citations Marta Guzmán, Javier Cortés et al. Cancer Research profile →
  11. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer
    2017 490 citations Sara M. Tolaney, Hope S. Rugo et al. profile →
  12. Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy
    2010 456 citations José Baselga, Andrew Wardley et al. Journal of Clinical Oncology profile →
  13. Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
    2018 348 citations Tiffany A. Traina, Joyce O’Shaughnessy et al. Journal of Clinical Oncology profile →
  14. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
    2021 330 citations Seock‐Ah Im, Eva Muñoz‐Couselo et al. profile →
  15. Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
    2020 279 citations Eva Muñoz‐Couselo, Joohyuk Sohn et al. profile →
  16. Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
    2021 275 citations Paolo Tarantino, Chiara Corti et al. profile →
  17. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
    2023 210 citations Hope S. Rugo, Aditya Bardia et al. profile →
  18. Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
    2022 176 citations Hope S. Rugo, Aditya Bardia et al. Journal of Clinical Oncology profile →
  19. Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial
    2022 162 citations José Manuel Pérez-García, Javier Cortés et al. profile →
  20. Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression
    2024 71 citations Aditya Bardia, Hope S. Rugo et al. Journal of Clinical Oncology profile →
  21. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
    2024 53 citations Javier Cortés, Sara A. Hurvitz et al. profile →
  22. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522
    2024 47 citations Javier Cortés, Rebecca Dent et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Javier Cortés Spain 76 21.1k 8.8k 8.0k 6.9k 5.3k 726 28.6k
Véronique Dièras France 63 18.5k 0.9× 9.5k 1.1× 6.3k 0.8× 4.3k 0.6× 3.1k 0.6× 354 23.3k
Luca Gianni Italy 72 20.5k 1.0× 6.0k 0.7× 8.3k 1.0× 8.2k 1.2× 5.7k 1.1× 309 30.7k
Mario Campone France 66 15.3k 0.7× 9.0k 1.0× 7.1k 0.9× 7.6k 1.1× 3.2k 0.6× 538 23.9k
Giuseppe Curigliano Italy 79 16.2k 0.8× 6.3k 0.7× 7.1k 0.9× 5.5k 0.8× 3.8k 0.7× 835 26.6k
Hiroji Iwata Japan 63 16.7k 0.8× 9.6k 1.1× 7.1k 0.9× 4.8k 0.7× 1.9k 0.4× 520 23.8k
Mark D. Pegram United States 56 17.8k 0.8× 4.6k 0.5× 4.9k 0.6× 6.8k 1.0× 8.5k 1.6× 221 23.8k
Seock‐Ah Im South Korea 70 23.9k 1.1× 14.0k 1.6× 9.0k 1.1× 7.2k 1.0× 4.1k 0.8× 661 32.9k
George W. Sledge United States 72 14.8k 0.7× 6.3k 0.7× 9.6k 1.2× 7.5k 1.1× 2.5k 0.5× 444 25.4k
Nadia Harbeck Germany 85 20.5k 1.0× 12.1k 1.4× 13.2k 1.7× 8.8k 1.3× 2.9k 0.6× 855 33.6k
John Crown Ireland 71 13.0k 0.6× 4.8k 0.5× 6.0k 0.7× 7.4k 1.1× 2.4k 0.4× 416 20.1k

Countries citing papers authored by Javier Cortés

Since Specialization
Citations

This map shows the geographic impact of Javier Cortés's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Javier Cortés with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Javier Cortés more than expected).

Fields of papers citing papers by Javier Cortés

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Javier Cortés. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Javier Cortés. The network helps show where Javier Cortés may publish in the future.

Co-authorship network of co-authors of Javier Cortés

This figure shows the co-authorship network connecting the top 25 collaborators of Javier Cortés. A scholar is included among the top collaborators of Javier Cortés based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Javier Cortés. Javier Cortés is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Zhijie, Judith A. Ermer, Ji Li, et al.. (2025). Selective tubulin-binding drugs induce pericyte phenotype switching and anti-cancer immunity. EMBO Molecular Medicine. 17(5). 1071–1100. 2 indexed citations
2.
3.
Bardia, Aditya, Hope S. Rugo, Sara M. Tolaney, et al.. (2024). Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. Journal of Clinical Oncology. 42(15). 1738–1744. 71 indexed citations breakdown →
4.
Untch, Michael, David Pérol, Erica L. Mayer, et al.. (2024). Disease-free survival as a surrogate for overall survival in HR+/HER2– early breast cancer: A correlation analysis. European Journal of Cancer. 202. 113977–113977. 7 indexed citations
5.
Antonarelli, Gabriele, Chiara Corti, Paolo Tarantino, et al.. (2023). Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure. ESMO Open. 8(4). 101608–101608. 21 indexed citations
6.
Cescon, David W., Peter Schmid, Hope S. Rugo, et al.. (2023). Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355. JNCI Journal of the National Cancer Institute. 116(5). 717–727. 7 indexed citations
7.
Dent, Rebecca, David W. Cescon, Thomas Bachelot, et al.. (2023). TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer. Future Oncology. 19(35). 2349–2359. 29 indexed citations
8.
Nadal‐Serrano, Mercedes, Marta Lalinde-Gutiérrez, Enrique J. Arenas, et al.. (2022). Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer. Cancer Research. 82(24). 4670–4679. 31 indexed citations
9.
Corti, Chiara, Gabriele Antonarelli, Carmine Valenza, et al.. (2022). Histology-agnostic approvals for antibody–drug conjugates in solid tumours: is the time ripe?. European Journal of Cancer. 171. 25–42. 13 indexed citations
10.
Cortés, Javier, Hope S. Rugo, David W. Cescon, et al.. (2022). Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. New England Journal of Medicine. 387(3). 217–226. 594 indexed citations breakdown →
11.
Rugo, Hope S., Aditya Bardia, Sara M. Tolaney, et al.. (2020). TROPiCS-02: A Phase III Study Investigating Sacituzumab Govitecan in the Treatment of HR+/HER2- Metastatic Breast Cancer. Future Oncology. 16(12). 705–715. 89 indexed citations
12.
Ramos, Javier, Juan F. Vega, Víctor L. Cruz, et al.. (2019). Hydrodynamic and Electrophoretic Properties of Trastuzumab/HER2 Extracellular Domain Complexes as Revealed by Experimental Techniques and Computational Simulations. International Journal of Molecular Sciences. 20(5). 1076–1076. 6 indexed citations
13.
Baselga, José, Robert E. Coleman, Javier Cortés, & Wolfgang Janni. (2017). Advances in the management of HER2-positive early breast cancer. Critical Reviews in Oncology/Hematology. 119. 113–122. 41 indexed citations
14.
Liu, Minetta C., Javier Cortés, & Joyce O’Shaughnessy. (2016). Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases. Cancer and Metastasis Reviews. 35(2). 323–332. 14 indexed citations
15.
Marco, V., et al.. (2014). Changes in Breast Cancer Reports after Pathology Second Opinion. The Breast Journal. 20(3). 295–301. 15 indexed citations
16.
Cortés, Javier, Sandra M. Swain, Iveta Kudaba, et al.. (2013). Absence of pharmacokinetic drug–drug interaction of pertuzumab with trastuzumab and docetaxel. Anti-Cancer Drugs. 24(10). 1084–1092. 19 indexed citations
17.
Bergh, Jonas, Igor Bondarenko, Mikhail Lichinitser, et al.. (2012). First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study. Journal of Clinical Oncology. 30(9). 921–929. 206 indexed citations
18.
Mattos‐Arruda, Leticia De & Javier Cortés. (2012). Advances in First-Line Treatment for Patients with HER-2+ Metastatic Breast Cancer. The Oncologist. 17(5). 631–644. 26 indexed citations
19.
20.
Scaltriti, Maurizio, Federico Rojo, Alberto Ocaña, et al.. (2007). Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer. JNCI Journal of the National Cancer Institute. 99(8). 628–638. 659 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Véronique Dièras Breakdown of academic impact, for papers by Luca Gianni Breakdown of academic impact, for papers by Mario Campone Breakdown of academic impact, for papers by Giuseppe Curigliano Breakdown of academic impact, for papers by Hiroji Iwata Breakdown of academic impact, for papers by Mark D. Pegram Breakdown of academic impact, for papers by Seock‐Ah Im Breakdown of academic impact, for papers by George W. Sledge Breakdown of academic impact, for papers by Nadia Harbeck Breakdown of academic impact, for papers by John Crown
Rankless by CCL
2026